“Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response.”, in ID Week 2014, Philadelphia, PA, 2014.
, “Assessment of Safety in Newborns of Mothers Participating in Clinical Trials of Vaccines Administered During Pregnancy”, Clin Infect Dis, vol. 59 Suppl 7, pp. S415-427, 2014.
, “Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children”, Pediatr Infect Dis J, vol. 33, pp. 865-871, 2014.
, “Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults”, Vaccine, vol. 29, pp. 5666-5674, 2011.
, “Determination of the 50% Human Infectious Dose for Norwalk Virus”, J Infect Dis, vol. 209, pp. 1016-1022, 2014.
, “Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes”, J Infect Dis, vol. 206, pp. 1069-1077, 2012.
, “Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis.”, Vaccine, vol. 37, no. 37, pp. 5535-5543, 2019.
, “Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults”, J Infec Dis, vol. 197, pp. 667-675, 2008.
, “Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming with an Antigenic Variant”, J Infec Dis, vol. 198, pp. 635-641, 2008.
, “Immunogenicity and Safety of Four Different Dosing Regimens of Anthrax Vaccine Adsorbed for Post-Exposure Prophylaxis for Anthrax in Adults”, Vaccine, vol. 32, pp. 6284-6293, 2014.
, “Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons”, J Infect Dis, vol. 206, pp. 811-820, 2012.
, “Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial”, JAMA, vol. 312, pp. 1420-1428, 2014.
, “Phase 2 Assessment of the Safety and Immunogenicity of Two Inactivated Pandemic Monovalent H1N1 Vaccines in Adults as a Component of the U.S. Pandemic Preparedness Plan in 2009”, Vaccine, vol. 13, pp. 4240-4248, 2012.
, “Phase II Randomized, Double-Blinded Comparison of a Single High Dose (5×10(8) TCID 50) of Modified Vaccinia Ankara Compared to a Standard Dose (1×10(8) TCID50) in Healthy Vaccinia-Naïve Individuals”, Vaccine, vol. 32, pp. 2732-2739, 2014.
, “Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations”, Vaccine, vol. 33, pp. 163-173, 2015.
, “PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4 T cell transcriptomal molecular signatures.”, Mucosal Immunol, vol. 11, no. 2, pp. 486-495, 2018.
, “Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure”, Clin Vaccine Immunol, vol. 16, pp. 558-566, 2009.
, “Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations”, J Infect Dis, vol. 206, pp. 828-837, 2012.
, “Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine”, J Infect Dis, vol. 212, pp. 525-530, 2015.
, “Safety and Immunogenicity of a Subvirion Inactivated Influenza a/H5N1 Vaccine With or Without Aluminum Hydroxide Among Healthy Elderly Adults”, Vaccine, vol. 27, pp. 5091-5095, 2009.
, “Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given Without or With Aluminum Hydroxide to Healthy Adults: Results of a Phase I-II Randomized Clinical Trial”, J Infec Dis, vol. 198, pp. 1309-1316, 2009.
, “Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults”, Vaccine, vol. 28, pp. 6367-6373, 2010.
, “Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial”, J Infect Dis, vol. 207, pp. 1888-1897, 2013.
,